跳转至内容
Merck
CN

PHR1042

Supelco

强的松

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

1-可的松, 17Α,21-二羟基-1,4-孕甾二烯-3,11,20-三酮, 去氢可的松, 强的松

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H26O5
CAS号:
分子量:
358.43
Beilstein:
2065301
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

certified reference material
pharmaceutical secondary standard

质量水平

Agency

traceable to BP 553
traceable to Ph. Eur. P2900000
traceable to USP 1559006

API类

prednisone

CofA

current certificate can be downloaded

技术

HPLC: suitable
gas chromatography (GC): suitable

mp

236-238 °C (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-30°C

SMILES字符串

O=C1C=C[C@@]2(C)C(CC[C@]([C@@](CC[C@@]3(C(CO)=O)O)([H])[C@]3(C)C4)([H])[C@]2([H])C4=O)=C1

InChI

1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

InChI key

XOFYZVNMUHMLCC-ZPOLXVRWSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

一般描述

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

应用

Prednisone may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by spectrophotometry and chromatography techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

分析说明

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

其他说明

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

附注

To see an example of a Certificate of Analysis for this material enter LRAA8969 in the slot below. This is an example certificate only and may not be the lot that you receive.

象形图

Health hazard

警示用语:

Warning

危险声明

预防措施声明

危险分类

STOT RE 2

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ian F Tannock et al.
The Lancet. Oncology, 14(8), 760-768 (2013-06-08)
Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor, thereby inhibiting angiogenesis. We assessed whether the
Jörg D Leuppi et al.
JAMA, 309(21), 2223-2231 (2013-05-23)
International guidelines advocate a 7- to 14-day course of systemic glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease (COPD). However, the optimal dose and duration are unknown. To investigate whether a short-term (5 days) systemic glucocorticoid treatment in
Ronald de Wit
European journal of cancer (Oxford, England : 1990), 41(4), 502-507 (2005-03-02)
Until now, the use of systemic chemotherapy for advanced androgen-independent prostate cancer has had very little to offer to patients. However, in 2004, two large randomised trials investigating docetaxel vs. mitoxantrone have both demonstrated survival improvements, and, in one of
O Teuffel et al.
Leukemia, 25(8), 1232-1238 (2011-04-30)
This systematic review and meta-analysis compared the efficacy and toxicity of dexamethasone (DEX) versus prednisone (PRED) for induction therapy in childhood acute lymphoblastic leukemia (ALL). We searched biomedical literature databases and conference proceedings for randomized controlled trials comparing DEX and
Charles J Ryan et al.
The Lancet. Oncology, 16(2), 152-160 (2015-01-21)
Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门